Patents Assigned to Cellvax
  • Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes
    Patent number: 12516125
    Abstract: The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 6, 2026
    Assignees: Universite de Lille, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Cellvax, University Paris Saclay
    Inventors: Nadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha
  • Antibody which is Directed Against Galectin-9 and is an Inhibitor of the Suppressor Activity of Regulatory T Lymphocytes
    Publication number: 20210107984
    Abstract: The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 15, 2021
    Applicants: Universite de Lille, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Cellvax, Universite Paris Saclay
    Inventors: Nadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha
  • Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes
    Patent number: 10899838
    Abstract: The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: January 26, 2021
    Assignees: Universite de Lille, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Cellvax, Universite Paris-Saclay
    Inventors: Nadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha